Tamás Ágh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tamás Ágh has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Marcell Csanádi
Syreon Research Institute, Budapest, Hungary
4 shared publications - Zoltán Kaló
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
4 shared publications - Jonas Mattsson
Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada
3 shared publications Manjiri Pawaskar
Formerly of Shire, 300 Shire Way, Lexington, MA, 02421, USA
3 shared publications- Zoltán Vokó
Syreon Research Institute, Budapest, Hungary
3 shared publications András Inotai
Syreon Research Institute, Budapest, Hungary
2 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (10)
Medication adherence in primary care: a practical handbook
- 13 October 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (10)
Open AccessMedication adherence in primary care: a practical handbook
- Open Access
- 14 May 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Variation in use of PROMs and geographical distribution in clinical trials of selected hematological diseases in Europe
- 14 May 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Open AccessVariation in use of PROMs and geographical distribution in clinical trials of selected hematological diseases in Europe
- 27 March 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (4) , 469-471
Medication adherence research: expert perspectives on key HEOR trends for 2026
- 27 March 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (4) , 469-471
Medication adherence research: expert perspectives on key HEOR trends for 2026
- 23 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (5) , 1516-1517
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
- 23 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (5) , 1516-1517
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
- 16 October 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (2) , 257-264
The hidden burden of atopic dermatitis in central and Eastern European countries
Atopic dermatitis (AD) imposes a hidden burden through its negative effects on quality of life and productivity. We aim to estimate this hidden burden in adults and adolescents in Central and Eastern European (CEE) countries. We created a burden of disease model to quantify AD's hidden burden. Humanistic burden was calculated by estimating the monetary value of quality-adjusted life years (QALYs) lost, using prevalence data from the Global Burden of Disease study, and gross domestic product (GDP) per capita for each country. Indirect economic burden was estimated based on productivity loss from absenteeism and presenteeism, adjusted for labor force participation and unemployment rates. Total hidden burden was determined by combining productivity losses and QALYs lost. QALY loss due to AD ranged from 1,832 to 58,596 annually in CEE countries, equating to 38 million to approximately 1 billion Euros per country. Productivity losses ranged from 3.6 to 148.9 million Euros annually. The total hidden burden of AD represents 0.11% to 0.43% of the GDP. Our estimates reflect significant differences in population sizes, prevalence, and economic strength among CEE countries. Adjusting findings to country-specific GDP provided insights into AD's true hidden burden, offering valuable information for decision-making.
- 16 October 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (2) , 257-264
The hidden burden of atopic dermatitis in central and Eastern European countries
Atopic dermatitis (AD) imposes a hidden burden through its negative effects on quality of life and productivity. We aim to estimate this hidden burden in adults and adolescents in Central and Eastern European (CEE) countries. We created a burden of disease model to quantify AD's hidden burden. Humanistic burden was calculated by estimating the monetary value of quality-adjusted life years (QALYs) lost, using prevalence data from the Global Burden of Disease study, and gross domestic product (GDP) per capita for each country. Indirect economic burden was estimated based on productivity loss from absenteeism and presenteeism, adjusted for labor force participation and unemployment rates. Total hidden burden was determined by combining productivity losses and QALYs lost. QALY loss due to AD ranged from 1,832 to 58,596 annually in CEE countries, equating to 38 million to approximately 1 billion Euros per country. Productivity losses ranged from 3.6 to 148.9 million Euros annually. The total hidden burden of AD represents 0.11% to 0.43% of the GDP. Our estimates reflect significant differences in population sizes, prevalence, and economic strength among CEE countries. Adjusting findings to country-specific GDP provided insights into AD's true hidden burden, offering valuable information for decision-making.
- Open Access
- 4 October 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1390629
Identifying and presenting key country-specific indicators related to medication adherence: a comprehensive study across European countries
This study tackles the critical challenge of medication non-adherence in healthcare by pinpointing indicators related to medication adherence (IRMAs) across 39 European countries and Israel. Utilizing a structured expert survey methodology within the European Network to Advance Best Practices and Technology on Medication Adherence (ENABLE; COST Action CA19132), our research identified key country-specific IRMAs and collected data on these indicators to understand the multifaceted nature of medication adherence. The research was conducted in two phases: firstly, defining key IRMAs through a two-round expert survey, and secondly, gathering country-specific data on these IRMAs through literature reviews and additional expert surveys. The study revealed a diverse range of 26 top-ranked IRMAs, including six related to country characteristics, four to social/economic factors, three each to therapy-related and patient-related factors, one to condition-related factors, and nine to healthcare system-related factors. The availability of country-specific data on these IRMAs varied among the countries, highlighting the need for more comprehensive data collection and research. The findings from this study not only underscore the complexity of predicting medication adherence but also lay the groundwork for developing targeted, country-specific interventions to improve adherence. Moreover, this research offers valuable insights for policymakers, highlighting the importance of understanding the multifaceted nature of medication adherence and offering a valuable resource in formulating targeted health policies to enhance health outcomes and reduce the economic burden associated with medication non-adherence.
- 4 October 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1390629
Open AccessIdentifying and presenting key country-specific indicators related to medication adherence: a comprehensive study across European countries
This study tackles the critical challenge of medication non-adherence in healthcare by pinpointing indicators related to medication adherence (IRMAs) across 39 European countries and Israel. Utilizing a structured expert survey methodology within the European Network to Advance Best Practices and Technology on Medication Adherence (ENABLE; COST Action CA19132), our research identified key country-specific IRMAs and collected data on these indicators to understand the multifaceted nature of medication adherence. The research was conducted in two phases: firstly, defining key IRMAs through a two-round expert survey, and secondly, gathering country-specific data on these IRMAs through literature reviews and additional expert surveys. The study revealed a diverse range of 26 top-ranked IRMAs, including six related to country characteristics, four to social/economic factors, three each to therapy-related and patient-related factors, one to condition-related factors, and nine to healthcare system-related factors. The availability of country-specific data on these IRMAs varied among the countries, highlighting the need for more comprehensive data collection and research. The findings from this study not only underscore the complexity of predicting medication adherence but also lay the groundwork for developing targeted, country-specific interventions to improve adherence. Moreover, this research offers valuable insights for policymakers, highlighting the importance of understanding the multifaceted nature of medication adherence and offering a valuable resource in formulating targeted health policies to enhance health outcomes and reduce the economic burden associated with medication non-adherence.
- 9 July 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (7) , 773-775
Bridging the gap: enhancing medication adherence through research and innovation
- 9 July 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (7) , 773-775
Bridging the gap: enhancing medication adherence through research and innovation
- Open Access
- 21 June 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (7) , 186
Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases
Despite the availability of affordable pharmaceuticals treating cardiovascular diseases (CVDs), many of the risk factors remain poorly controlled. Fixed-dose combinations (FDCs), a form of incremental innovation, have already demonstrated improvements over combinations of single medicines in adherence and hard clinical endpoints. Nevertheless, there are many barriers related to the wider use of FDCs in CVDs. Our aim was to identify these barriers and explore system-level facilitators from a multi-stakeholder perspective. Identified barriers include (i) hurdles in evidence generation for manufacturers, (ii) limited acceptance of adherence as an endpoint by clinical guideline developers and policymakers, (iii) limited options for a price premium for incremental innovation for healthcare payers, (iv) limited availability of real-world evidence, and (v) methodological issues to measure improved adherence. Initiatives to standardize and link healthcare databases in European countries, movements towards improved patient centricity in healthcare, and extended value assessment provide opportunities to capture the benefits of FDCs. Still, there is an emerging need to facilitate the generalizability of sporadic clinical evidence across different FDCs and to improve adherence measures. Finally, healthcare payers need to be convinced to pay a fair premium price for the added value of FDCs to incentivize incremental innovation in CVD treatment.
- 21 June 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (7) , 186
Open AccessFacilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases
Despite the availability of affordable pharmaceuticals treating cardiovascular diseases (CVDs), many of the risk factors remain poorly controlled. Fixed-dose combinations (FDCs), a form of incremental innovation, have already demonstrated improvements over combinations of single medicines in adherence and hard clinical endpoints. Nevertheless, there are many barriers related to the wider use of FDCs in CVDs. Our aim was to identify these barriers and explore system-level facilitators from a multi-stakeholder perspective. Identified barriers include (i) hurdles in evidence generation for manufacturers, (ii) limited acceptance of adherence as an endpoint by clinical guideline developers and policymakers, (iii) limited options for a price premium for incremental innovation for healthcare payers, (iv) limited availability of real-world evidence, and (v) methodological issues to measure improved adherence. Initiatives to standardize and link healthcare databases in European countries, movements towards improved patient centricity in healthcare, and extended value assessment provide opportunities to capture the benefits of FDCs. Still, there is an emerging need to facilitate the generalizability of sporadic clinical evidence across different FDCs and to improve adherence measures. Finally, healthcare payers need to be convinced to pay a fair premium price for the added value of FDCs to incentivize incremental innovation in CVD treatment.
- 10 November 2023
- Published by Elsevier in Value in Health
- Vol. 27 (2) , 133-142
Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report
- 10 November 2023
- Published by Elsevier in Value in Health
- Vol. 27 (2) , 133-142
Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report